Copyright
©The Author(s) 2022.
World J Clin Cases. Nov 6, 2022; 10(31): 11391-11402
Published online Nov 6, 2022. doi: 10.12998/wjcc.v10.i31.11391
Published online Nov 6, 2022. doi: 10.12998/wjcc.v10.i31.11391
Table 2 Baseline clinical characteristics of all patients
Characteristic | Control group (n = 38) | TCM group (n = 40) | P value |
Age (yr) | 11.07 ± 2.28 | 11.51 ± 2.77 | 0.338 |
Female sex, n (%) | 25 (65.8) | 28 (70) | 0.690 |
Weight (kg) | 39.18 ± 11.55 | 41.61 ± 15.55 | 0.582 |
Duration of SLE (years) | 0.65 ± 1.37 | 0.78 ± 1.21 | 0.607 |
Duration of LN (years) | 0.15 ± 0.41 | 0.17 ± 0.28 | 0.559 |
Serum creatinine (μmol/L) | 61.73 ± 46.68 | 51.46 ± 22.52 | 0.127 |
White blood cell count | 5.03 ± 3.22 | 5.83 ± 3.20 | 0.201 |
NE (%) | 53.85 ± 19.54 | 57.56 ± 15.33 | 0.489 |
HGB (g/L) | 100.18 ± 16.93 | 105.85 ± 23.73 | 0.308 |
PT (s) | 10.45 ± 0.93 | 11.23 ± 2.09 | 0.115 |
APTT (s) | 35.48 ± 17.25 | 37.6 ± 16.17 | 0.577 |
D-D (mg/L) | 1.08 ± 1.64 | 1.02 ± 1.32 | 0.161 |
Serum albumin (g/L) | 29.23 ± 5.99 | 30.92 ± 4.61 | 0.167 |
Urine protein (g/24 h) | 1.29 ± 1.81 | 1.32 ± 1.11 | 0.314 |
Urine RBC count/HPF | 26.17 ± 37.92 | 25.65 ± 37.59 | 0.24 |
Serum C3 (g/L) | 0.28 ± 0.18 | 0.39 ± 0.28 | 0.101 |
Serum C4 (g/L) | 0.05 ± 0.04 | 0.06 ± 0.05 | 0.782 |
BUN (IU/mL) | 6.94 ± 3.89 | 5.72 ± 2.31 | 0.057 |
ALT (mmol/L) | 33.20 ± 28.04 | 32.88 ± 36.34 | 0.730 |
AST (mmol/L) | 40.00 ± 41.21 | 39.61 ± 43.37 | 0.957 |
SLEDAI | 15.57 ± 5.01 | 14.07 ± 3.49 | 0.315 |
ds-DNA postive, n (%) | 28 (73.6) | 33 (82.5) | 0.345 |
- Citation: Cao TT, Chen L, Zhen XF, Zhao GJ, Zhang HF, Hu Y. Dan Bai Xiao Formula combined with glucocorticoids and cyclophosphamide for pediatric lupus nephritis: A pilot prospective study. World J Clin Cases 2022; 10(31): 11391-11402
- URL: https://www.wjgnet.com/2307-8960/full/v10/i31/11391.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i31.11391